On Wednesday, Encompass Health earned a positive adjustment to its Relative Strength (RS) Rating, from 80 to 83.
IBD's unique rating measures price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the best-performing stocks tend to have an RS Rating of above 80 as they begin their biggest climbs.
Looking For The Best Stocks To Buy And Watch? Start Here
Encompass Health is trying to complete a cup with handle with a 103.83 entry. See if the stock can break out in volume at least 40% higher than normal.
Taking a look at top and bottom line numbers, Encompass Health has posted two quarters of accelerating earnings growth. Sales growth has also increased during the same period.
The company holds the No. 1 rank among its peers in the Medical-Outpatient/Home Care industry group. Pediatrix Medical and Fresenius Medical Care are also among the group's highest-rated stocks.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
